MX388408B - Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv - Google Patents
Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbvInfo
- Publication number
- MX388408B MX388408B MX2019002678A MX2019002678A MX388408B MX 388408 B MX388408 B MX 388408B MX 2019002678 A MX2019002678 A MX 2019002678A MX 2019002678 A MX2019002678 A MX 2019002678A MX 388408 B MX388408 B MX 388408B
- Authority
- MX
- Mexico
- Prior art keywords
- tlr7 agonist
- capsid assembly
- hbv capsid
- combined treatment
- assembly inhibitor
- Prior art date
Links
- 229940118186 HBV capsid assembly inhibitor Drugs 0.000 title abstract 2
- 229940124615 TLR 7 agonist Drugs 0.000 title 1
- 208000002672 hepatitis B Diseases 0.000 abstract 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se dirige a composiciones y métodos para tratar infección de virus de hepatitis B virus. En particular, la presente invención se dirige a una terapia de combinación que comprende administración de un agonista de TLR7 y un inhibidor de montaje de cápsida de HBV para el uso en el tratamiento de paciente con hepatitis B crónica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016098892 | 2016-09-13 | ||
| PCT/EP2017/072671 WO2018050571A1 (en) | 2016-09-13 | 2017-09-11 | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019002678A MX2019002678A (es) | 2019-05-20 |
| MX388408B true MX388408B (es) | 2025-03-19 |
Family
ID=59859071
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002678A MX388408B (es) | 2016-09-13 | 2017-09-11 | Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv |
| MX2021014771A MX2021014771A (es) | 2016-09-13 | 2019-03-07 | Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014771A MX2021014771A (es) | 2016-09-13 | 2019-03-07 | Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11337982B2 (es) |
| EP (2) | EP3512556B1 (es) |
| JP (2) | JP7101663B2 (es) |
| KR (1) | KR102497701B1 (es) |
| CN (1) | CN109715214B (es) |
| AU (1) | AU2017326400B2 (es) |
| BR (1) | BR112019004560A2 (es) |
| CA (1) | CA3034185A1 (es) |
| ES (1) | ES2894605T3 (es) |
| IL (2) | IL264926B (es) |
| MX (2) | MX388408B (es) |
| PL (1) | PL3512556T3 (es) |
| TW (1) | TWI720250B (es) |
| WO (1) | WO2018050571A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3114128T3 (pl) * | 2014-03-07 | 2019-06-28 | F. Hoffmann-La Roche Ag | Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B |
| CN107427514B (zh) | 2015-03-16 | 2021-07-13 | 豪夫迈·罗氏有限公司 | 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗 |
| CA3034185A1 (en) * | 2016-09-13 | 2018-03-22 | F. Hoffmann-La Roche Ag | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
| EP3645516A4 (en) | 2017-06-27 | 2021-07-07 | Janssen Pharmaceutica NV | HETEROARYLDIHYDROPYRIMIDE DERIVATIVES AND METHODS OF TREATMENT OF HEPATITIS B INFECTIONS |
| WO2019155042A1 (en) | 2018-02-12 | 2019-08-15 | F. Hoffmann-La Roche Ag | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| PE20211456A1 (es) * | 2018-02-28 | 2021-08-05 | Hoffmann La Roche | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado |
| US11554120B2 (en) * | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| CA3124317A1 (en) * | 2018-12-20 | 2020-06-25 | Janssen Pharmaceutica Nv | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections |
| AU2020249331B2 (en) | 2019-03-25 | 2026-02-05 | F. Hoffmann-La Roche Ag | Solid forms of a compound of HBV core protein allosteric modifier |
| TW202122392A (zh) * | 2019-07-31 | 2021-06-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 二氫嘧啶衍生物及其於治療hbv感染或hbv誘發的疾病之用途 |
| EP4031140A1 (en) * | 2019-09-20 | 2022-07-27 | F. Hoffmann-La Roche AG | Method of treating hbv infection using a core protein allosteric modulator |
| CN119679953A (zh) * | 2023-09-22 | 2025-03-25 | 苏州申拓医药科技有限公司 | 含tlr7/8选择性激动剂和hbv衣壳装配抑制剂的药物组合物及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4189048B2 (ja) | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
| DE10012824A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013126A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| WO2005085462A1 (en) | 2004-02-27 | 2005-09-15 | Dsm Ip Assets B.V. | Enzymatic preparation of an enantiomerically enriched beta-2-amino acids |
| WO2006033995A2 (en) | 2004-09-16 | 2006-03-30 | Valeant Research And Development | Thiazolidin-4-ones having anti-hepatitis b activity |
| EA200702235A1 (ru) | 2005-05-04 | 2008-04-28 | Пфайзер Лимитед | Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с |
| CA2621809A1 (en) | 2005-09-22 | 2007-04-05 | The Scripps Research Institute | Alkoxy indolinone based protein kinase inhibitors |
| JP2009542645A (ja) * | 2006-07-05 | 2009-12-03 | アストラゼネカ・アクチエボラーグ | Tlr7のモジュレーターとして作用する8−オキソアデニン誘導体 |
| GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| WO2009067547A1 (en) | 2007-11-19 | 2009-05-28 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| CN101239980B (zh) | 2008-02-18 | 2011-06-22 | 靳广毅 | 免疫受体调节剂偶联体前体和偶联体及其应用 |
| EP2098526B1 (en) | 2008-02-22 | 2014-01-15 | Neurotune AG | Nitrogen-containing bicyclic compounds active on chronic pain conditions |
| JP5816087B2 (ja) | 2008-08-29 | 2015-11-18 | エンメエッセディ・イタリア・エッセ・エッレ・エッレ | Smoアンタゴニストとしての飽和二環式複素環誘導体 |
| UY32306A (es) | 2008-12-09 | 2010-07-30 | Gilead Sciences Inc | Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos |
| WO2010069147A1 (zh) | 2008-12-17 | 2010-06-24 | 张中能 | 二氢嘧啶类化合物、其组合物及其应用 |
| US20110150836A1 (en) | 2009-12-22 | 2011-06-23 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
| CN102372706A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| EP2794565B1 (en) | 2011-12-21 | 2017-07-26 | Novira Therapeutics Inc. | Hepatitis b antiviral agents |
| MX2014011749A (es) | 2012-03-31 | 2015-01-22 | Hoffmann La Roche | 4-metil-dihidropirimidinas novedosas para el tratamiento y la prolifaxis de la infeccion por el virus de la hepatitis b. |
| CA2881322A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| US8993771B2 (en) * | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| PE20151951A1 (es) | 2013-05-17 | 2015-12-26 | Hoffmann La Roche | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b |
| CN104650069B (zh) | 2013-11-19 | 2019-04-19 | 广东东阳光药业有限公司 | 4-甲基二氢嘧啶类化合物及其在药物中的应用 |
| PL3114128T3 (pl) | 2014-03-07 | 2019-06-28 | F. Hoffmann-La Roche Ag | Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B |
| CN112898308B (zh) | 2014-08-15 | 2026-08-07 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| EP3204392A1 (en) | 2014-10-11 | 2017-08-16 | F. Hoffmann-La Roche AG | Compounds for use in the treatment of infectious diseases |
| CN107427514B (zh) * | 2015-03-16 | 2021-07-13 | 豪夫迈·罗氏有限公司 | 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗 |
| NZ775222A (en) * | 2015-05-08 | 2024-09-27 | Hoffmann La Roche | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
| RU2751349C2 (ru) | 2016-08-29 | 2021-07-13 | Ф. Хоффманн-Ля Рош Аг | 7-замещенные сульфонимидоилпуриноны для лечения и профилактики вирусной инфекции |
| CA3034185A1 (en) * | 2016-09-13 | 2018-03-22 | F. Hoffmann-La Roche Ag | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
-
2017
- 2017-09-11 CA CA3034185A patent/CA3034185A1/en active Pending
- 2017-09-11 EP EP17767788.7A patent/EP3512556B1/en active Active
- 2017-09-11 WO PCT/EP2017/072671 patent/WO2018050571A1/en not_active Ceased
- 2017-09-11 CN CN201780054239.9A patent/CN109715214B/zh not_active Expired - Fee Related
- 2017-09-11 EP EP21188992.8A patent/EP3970750A1/en not_active Withdrawn
- 2017-09-11 JP JP2019513914A patent/JP7101663B2/ja not_active Expired - Fee Related
- 2017-09-11 MX MX2019002678A patent/MX388408B/es unknown
- 2017-09-11 ES ES17767788T patent/ES2894605T3/es active Active
- 2017-09-11 BR BR112019004560A patent/BR112019004560A2/pt not_active Application Discontinuation
- 2017-09-11 KR KR1020197010363A patent/KR102497701B1/ko active Active
- 2017-09-11 PL PL17767788T patent/PL3512556T3/pl unknown
- 2017-09-11 TW TW106130951A patent/TWI720250B/zh not_active IP Right Cessation
- 2017-09-11 AU AU2017326400A patent/AU2017326400B2/en not_active Ceased
-
2019
- 2019-02-20 IL IL264926A patent/IL264926B/en unknown
- 2019-03-07 MX MX2021014771A patent/MX2021014771A/es unknown
- 2019-03-13 US US16/351,922 patent/US11337982B2/en not_active Expired - Fee Related
-
2021
- 2021-10-25 IL IL287545A patent/IL287545B2/en unknown
-
2022
- 2022-07-04 JP JP2022107537A patent/JP2022130672A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201811371A (zh) | 2018-04-01 |
| EP3512556B1 (en) | 2021-08-18 |
| KR102497701B1 (ko) | 2023-02-09 |
| JP7101663B2 (ja) | 2022-07-15 |
| ES2894605T3 (es) | 2022-02-15 |
| PL3512556T3 (pl) | 2021-12-27 |
| JP2022130672A (ja) | 2022-09-06 |
| US20190298726A1 (en) | 2019-10-03 |
| CN109715214A (zh) | 2019-05-03 |
| IL287545B2 (en) | 2023-02-01 |
| CN109715214B (zh) | 2022-03-04 |
| WO2018050571A1 (en) | 2018-03-22 |
| CA3034185A1 (en) | 2018-03-22 |
| EP3512556A1 (en) | 2019-07-24 |
| IL287545B (en) | 2022-10-01 |
| JP2019526610A (ja) | 2019-09-19 |
| AU2017326400B2 (en) | 2023-03-30 |
| AU2017326400A1 (en) | 2019-02-21 |
| MX2019002678A (es) | 2019-05-20 |
| KR20190053219A (ko) | 2019-05-17 |
| US11337982B2 (en) | 2022-05-24 |
| MX2021014771A (es) | 2022-01-18 |
| IL264926B (en) | 2021-12-01 |
| EP3970750A1 (en) | 2022-03-23 |
| TWI720250B (zh) | 2021-03-01 |
| IL287545A (en) | 2021-12-01 |
| BR112019004560A2 (pt) | 2019-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002230A1 (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb. | |
| MX2019002678A (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv. | |
| BR112018009009A8 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
| UY37581A (es) | Compuestos para el tratamiento de la infección por virus de la hepatitis b | |
| CL2019001433A1 (es) | Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684) | |
| UY37252A (es) | Compuestos para el tratamiento de infección por virus de la hepatitis b | |
| MX2020011808A (es) | Combinaciones y metodos que comprenden un inhibidor del ensamblaje de la capside. | |
| MX2018014573A (es) | Vacuna contra el virus del zika. | |
| CL2018002549A1 (es) | Eliminación del virus de la hepatitis b con agentes antivirales | |
| CR20160520A (es) | Oligómeros y conjugados de oligómeros | |
| MX2022007908A (es) | Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv. | |
| GT201500020A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2016002269A1 (es) | Moduladores alostéricos del núcleo proteico de la hepatitis b. | |
| CO2019009215A2 (es) | Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c | |
| MX383447B (es) | Combinación de un inhibidor de ensamblaje de cápsido y peginterferón alfa-2a y sus usos para tratar infecciones por virus de la hepatitis b (vhb). | |
| MX2016004580A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| MX378872B (es) | Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia. | |
| AR111908A1 (es) | Composiciones terapéuticas y métodos de tratamiento de hepatitis b | |
| MX373231B (es) | Agente anticancerigeno. | |
| CL2015001971A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas. | |
| DOP2016000336A (es) | Derivados de isoindolina para uso en el tratamiento de una infeccion viral | |
| MX381896B (es) | Compuestos de tiazolida para el tratamiento de infecciones virales. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| CL2018001946A1 (es) | Virus atenuados de bronquitis infecciosa. |